Treatment response rates to the 177Lu-PSMA-617 and NOX66 combination were high with a 61% PSA50, even though most men in this trial had high-volume disease, baseline anemia, high baseline opiate requirements, and 95% had undergone 2 lines of taxane therapy. The gene discussed is FOLH1; the disease is anemia (phenotype).